Medication recalls, shortages, FDA safety communications, black-box warnings, and practical medication risk updates.
FDA warnings, shortages, recalls, medication risks, safety notices
Prescriptions; Health Insurance; Medical Care
FDA’s 2026 GLP-1 crackdown targets compounded or illegally marketed products, not approved brands. Here’s how patients can verify what they’re taking.
With semaglutide and tirzepatide shortages resolved, the FDA is tightening scrutiny of mass-marketed compounded GLP-1s. Here is what changed and what patients should ask now.
The FDA says some telehealth companies used false or misleading marketing for compounded GLP-1 drugs. Here is what that means for patients, how compounded products differ from approved drugs, and what to check before ordering online.
FDA has stepped up action against compounded GLP-1 weight-loss drugs sold online and through telehealth. Here’s what changed in 2026, why the agency says shortages no longer justify broad copycat compounding, what safety problems it has flagged, and how to protect yourself before buying.
FDA says Silintan capsules sold online nationwide contained undeclared meloxicam, an NSAID that can raise the risk of bleeding, ulcers, kidney injury, heart attack, and stroke in some users.
Severe low blood sugar remains a preventable but dangerous complication of diabetes. Updated 2026 guidelines from the American Diabetes Association emphasize broader continuous glucose monitoring, safer medication choices, and ready-to-use glucagon — with important insurance implications for older adults.
Using headache medicines too often can sometimes make headaches worse instead of better. Here’s what U.S. experts say about medication overuse headache—how it happens, who’s at risk, and how to break the cycle safely.
Drug shortages remain a nationwide issue in early 2026. Here’s what it means when a medication appears on the FDA’s Drug Shortages list, how shortages differ from recalls, and what patients should do to protect their care.
The FDA has issued recent safety communications about compounded versions of popular GLP-1 drugs such as semaglutide and tirzepatide, warning of dosing errors, ingredient differences, and potential contamination. Here’s what patients and families should understand about the risks, legal limits, and how to protect themselves.
Recent FDA safety communications about compounded medications and ongoing drug supply shifts are raising new questions for patients. Here’s what to know about prescription safety, shortages, and how to protect yourself.
Drug recalls can sound alarming, but not all recalls carry the same level of risk. Here’s how the FDA’s recall system works, what different classifications mean, and what patients should do if a medication they use is recalled.
Updated recommendations for rheumatoid arthritis emphasize starting treatment early, monitoring closely, and addressing related health risks. Here’s what that means for patients and families in the United States.
From a multistate Salmonella outbreak linked to green powder supplements to recalls for hidden prescription drugs, federal agencies are stepping up oversight of dietary supplements. Here’s what that means for everyday consumers.
Drug recalls can be confusing and concerning. Here’s how the FDA handles recalls in the U.S., what different recall classes mean, and what patients and families should do if a medication they use is recalled.
Federal health agencies continue to monitor the safety of breast implants, including rare cancer risks and other complications. Here’s what the evidence shows, who may be affected, and what to discuss with your surgeon.
Prescription drug shortages continue to affect patients across the United States. Here’s what the FDA says, why shortages happen, and practical steps you can take if your medication is hard to find.
End of content
End of content
